Diabetes Mellitus, Type 2 Clinical Trials

Completed

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

NCT00602472

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1218.18.54001 Boehringer Ingelheim Investigational Site Capital Federal, Argentina

1218.18.54002 Boehringer Ingelheim Investigational Site Capital Federal, Argentina

1218.18.54004 Boehringer Ingelheim Investigational Site Capital Federal, Argentina

1218.18.54005 Boehringer Ingelheim Investigational Site Capital Federal, Argentina

View all 100 locations

View Trial Details

Completed

Comprehensive Add on Study in Japan

NCT01204294

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1218.78.008 Boehringer Ingelheim Investigational Site Akishima, Tokyo, Japan

1218.78.030 Boehringer Ingelheim Investigational Site Amagasaki, Hyogo, Japan

1218.78.017 Boehringer Ingelheim Investigational Site Annaka, Gunma, Japan

1218.78.006 Boehringer Ingelheim Investigational Site Aomori, Aomori, Japan

View all 43 locations

View Trial Details

Completed

Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet

NCT01383356

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1288.19.1 Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada

View Trial Details

Completed

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

NCT00996658

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1218.61.01028 Boehringer Ingelheim Investigational Site Escondido, California, United States

1218.61.01014 Boehringer Ingelheim Investigational Site Greenbrae, California, United States

1218.61.01015 Boehringer Ingelheim Investigational Site Los Angeles, California, United States

1218.61.01042 Boehringer Ingelheim Investigational Site Paramount, California, United States

View all 52 locations

View Trial Details

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

NCT00328172

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1218.5.10020 Boehringer Ingelheim Investigational Site Chula Vista, California, United States

1218.5.10001 Boehringer Ingelheim Investigational Site La Jolla, California, United States

1218.5.10007 Boehringer Ingelheim Investigational Site Walnut Creek, California, United States

1218.5.10041 Boehringer Ingelheim Investigational Site Denver, Colorado, United States

View all 71 locations

View Trial Details

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

NCT01175824

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +5 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Mar del Plata, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ramos Mejía, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Porto Alegre, Brazil

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. São Paulo, Brazil

View all 18 locations

View Trial Details

Completed

Glucose Reduction by Early Acarbose Treatment in Basal Insulin

NCT00970528

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: Wŏnju, Gang''weondo, South Korea

Busan, Korea, South Korea

Gyeonggi-do, Korea, South Korea

Gyeonggi-do, Korea, South Korea

View Trial Details

Completed

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

NCT00621140

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1218.16.38605 Boehringer Ingelheim Investigational Site Krapinske Toplice, Croatia

1218.16.38604 Boehringer Ingelheim Investigational Site Slavonski Brod, Croatia

1218.16.91009 Boehringer Ingelheim Investigational Site Andhra Pradesh, India

1218.16.91002 Boehringer Ingelheim Investigational Site Bangalore, India

View all 69 locations

View Trial Details

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

NCT00641043

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations: 1218.15.43004 Boehringer Ingelheim Investigational Site Feldkirch, Austria

1218.15.43001 Boehringer Ingelheim Investigational Site Graz, Austria

1218.15.43003 Boehringer Ingelheim Investigational Site Vienna, Austria

1218.15.43005 Boehringer Ingelheim Investigational Site Vienna, Austria

View all 43 locations

View Trial Details

Completed

ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?

NCT01460446

Conditions: Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +6 more
Locations: Aschaffenburg, Germany

Augsburg, Germany

Berlin, Germany

Berlin, Germany

View all 33 locations

View Trial Details

Diabetes Mellitus, Type 2

Diabetes Mellitus, Type 2 trial results

Related conditions